Health delivery track
The combination of life sciences and tech in the diagnostic and monitoring space opens the door to a broad range of business models – some traditional and some novel. Join the panel as they discuss their disparate experiences and share advice on how you can fine-tune your path to profitability.
Bram has over 20 years of leadership in BioPharma and precision medicine. He held C-level roles at Eagle Genomics and SOPHiA Genetics, enhancing platform innovation and US presence. As VP at Foundation Medicine, he expanded its global precision medicine platform. As CEO of Prometheus Laboratories, he integrated it into Nestlé Health Science and served as Head of Brain Health. Earlier, he held senior roles at UCB Pharma and Eli Lilly, launching CNS medicines globally. Bram’s board experience includes Mantis Photonics and Cerecin Inc. He is passionate about patient care and values diverse teams. His strategic vision and leadership have consistently driven growth and shareholder value.
Dr Jason Mellad is Co-founder and CEO of OtoImmune, a precision immunology company focused on revolutionising the early detection, management and treatment of autoimmune and other immune-mediated inflammatory diseases. Previously he was co-founder and CEO of life science venture builder fund, Start Codon, and epigenomic biomarker discovery pioneer, Cambridge Epigenetix (now Biomodal). Dr Mellad holds a PhD in Medicine from the University of Cambridge.
Marta's academic training at Dalhousie University and Imperial College London gave her a rare combination of molecular microbiology and large-scale automation, the technical foundation that underpins how Salient Bio builds and scales its platforms. She co-founded Salient Bio to advance the applications of automation in diagnostics, and to bridge the gap between R&D and real-world clinical applications, translating microbiome science into wellness and diagnostic tools that can meaningfully change patient outcomes.
She heads up Salient's strategy, partnerships, and commercial functions, driven by a conviction that preventative healthcare and access to at-home, non-invasive diagnostics have the potential to greatly improve patient outcomes.
